Literature DB >> 9794563

The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients.

M P Kooistra1, J J Marx.   

Abstract

BACKGROUND: Intravenous iron supplementation is often necessary in recombinant human erythropoietin (r-HuEPO)-treated haemodialysis (HD) patients, but rarely in r-HuEPO-treated peritoneal dialysis (PD) patients. This may be due to differences in iron absorption or blood loss.
METHOD: Iron absorption (whole-body counting after ingestion of a radiolabelled iron test dose) and iron metabolism were compared in eight iron-replete rHuEPO-treated PD patients (serum ferritin 100-500 microg/l) and 68 healthy iron-replete controls (sufficient iron in bone marrow specimen).
RESULTS: Mucosal uptake (13.4+/-9.8%), mucosal transfer (0.34+/-0.18) and iron retention (4.9+/-4.0) in PD patients was significantly lower than in controls (42.9+/-18.8%, P < 0.0001, 0.63+/-0.18, P < 0.0001, and 28.0+/-16.7%, P<0.0001).
CONCLUSION: Iron absorption is impaired in PD patients, as we have shown previously for HD patients. One reason for higher iron needs in HD patients may be higher blood losses due to the dialysis procedure and blood sampling for laboratory tests.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794563     DOI: 10.1093/ndt/13.10.2578

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

Review 1.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

2.  Iron inhibits respiratory burst of peritoneal phagocytes in vitro.

Authors:  Kamil Gotfryd; Aleksandra Jurek; Piotr Kubit; Andrzej Klein; Bohdan Turyna
Journal:  ISRN Urol       Date:  2011-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.